Anteris Technologies Global (ASX:AVR)
ASX announcement history & article coverage
Transparent by design.
Announcments by Anteris Technologies Global (ASX:AVR) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Statement of CDIs on issue - AVR
Form S-3 Registration Statement
Notification of cessation of securities - AVR
Notification regarding unquoted securities - AVR
Application for quotation of securities - AVR
Change of Director's Interest Notice
PARADIGM - French Regulatory Clearance
Change of Director's Interest Notice
Statement of CDIs on issue - AVR
Notification of cessation of securities - AVR
Prospectus Supplement and Sales Agreement
Anteris Technologies launches $250M at-the-market stock offering to fund heart valve development
Initial Director's Interest Notice x 2
Board Appointments
Results for the First Quarter of 2026
Anteris raises $320M, advances PARADIGM Trial with US enrollment and reports Q1 2026 cash outflows of $28.7M
Quarterly Results Announcement and SEC Form 10-Q
Anteris reports Q1 2026 net loss of $22.9M, raises $320M capital, advances DurAVR clinical trial
First US Patients Treated in Global Pivotal PARADIGM Trial
Anteris Technologies Treats First U.S. Patients in Global PARADIGM Heart Valve Trial
Statement of CDIs on issue - AVR
Termination of a Material Definitive Agreement
Notification regarding unquoted securities - AVR
Notification of cessation of securities - AVR
CMS Reimbursement Secured for PARADIGM Trial
Anteris Technologies Secures U.S. Medicare Reimbursement for PARADIGM Trial
Notification regarding unquoted securities - AVR
Entry into a Material Definitive Agreement
Notification regarding unquoted securities - AVR